FRUZAQLA Hard capsule Ref.[111509] Active ingredients: Fruquintinib

Source: European Medicines Agency (EU)  Revision Year: 2024  Publisher: Takeda Pharmaceuticals International AG Ireland Branch, Block 2 Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, D02 HW68, Ireland, medinfoEMEA@takeda.com

Product name and form

FRUZAQLA 1 mg hard capsules.

FRUZAQLA 5 mg hard capsules.

Pharmaceutical Form

Hard capsule.

FRUZAQLA 1 mg hard capsules: Opaque hard gelatin capsule, size 3 (approximate length 16 mm), with a yellow cap and a white body imprinted with “HM013” over “1mg” in black ink.

FRUZAQLA 5 mg hard capsules: Opaque hard gelatin capsule, size 1 (approximate length 19 mm), with a red cap and a white body imprinted with “HM013” over “5mg” in black ink.

Qualitative and quantitative composition

FRUZAQLA 1 mg hard capsules

Each hard capsule contains 1 mg fruquintinib.

Excipients with known effect: Each 1 mg hard capsule contains 0.0247 mg of tartrazine (E102) and 0.0004 mg of sunset yellow FCF (E110) colourants.

FRUZAQLA 5 mg hard capsules

Each hard capsule contains 5 mg fruquintinib.

Excipient with known effect: Each 5 mg hard capsule contains 0.1829 mg of Allura red AC (E129) colourant.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Fruquintinib

Fruquintinib is a selective tyrosine kinase inhibitor of VEGFR-1, -2, and -3 with antitumor effects resulting from suppression of tumour angiogenesis.

List of Excipients

Capsule content:

Maize starch
Cellulose, microcrystalline (E460)
Talc (E553b)

Capsule shell (1 mg hard capsules only):

Gelatin
Titanium dioxide (E171)
Tartrazine (E102)
Sunset yellow FCF (E110)

Capsule shell (5 mg hard capsules only):

Gelatin
Titanium dioxide (E171)
Allura red AC (E129)
Brilliant blue FCF (E133)

Printing ink:

Shellac (E904)
Propylene glycol (E1520)
Potassium hydroxide
Iron oxide black (E172)

Pack sizes and marketing

High-density polyethylene (HDPE) bottle (45 mL) with polypropylene (PP) child-resistant closure and a HDPE desiccant cartridge containing silica gel. The desiccant must be kept inside the bottle.

Each bottle contains 21 hard capsules. Each bottle is packaged in a carton.

Marketing authorization holder

Takeda Pharmaceuticals International AG Ireland Branch, Block 2 Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, D02 HW68, Ireland, medinfoEMEA@takeda.com

Marketing authorization dates and numbers

EU/1/24/1827/001
EU/1/24/1827/002

Date of first authorisation: 20 June 2024

Drugs

Drug Countries
FRUZAQLA Austria, France, Lithuania, Romania, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.